Combination approach shows promise for treating rare, aggressive cancers
University of California, Los Angeles (UCLA), Health SciencesUCLA investigators have shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.